°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

±âħ, °¨±â, ¾Ë·¹¸£±â(CCA) : ÇöÀç ¹× ÇâÈÄ ¼¿ÇÁÄɾî CCA ½ÃÀå

Cough, Cold & Allergy Report - Exploring the Current & Future Self-Care CCA Market

¸®¼­Ä¡»ç Nicholas Hall & Company
¹ßÇàÀÏ 2020³â 11¿ù »óǰ ÄÚµå 953767
ÆäÀÌÁö Á¤º¸ ¿µ¹® 328 Pages
°¡°Ý
¡Ì 9,000 £Ü 13,760,000 PDF (Site License)
¡Ì 12,000 £Ü 18,347,000 PDF (Global License)


±âħ, °¨±â, ¾Ë·¹¸£±â(CCA) : ÇöÀç ¹× ÇâÈÄ ¼¿ÇÁÄɾî CCA ½ÃÀå Cough, Cold & Allergy Report - Exploring the Current & Future Self-Care CCA Market
¹ßÇàÀÏ : 2020³â 11¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹® 328 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÁÖ¿ä 10°³±¹ÀÇ ±âħ¡¤°¨±â¡¤¾Ë·¹¸£±â(CCA) ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ½ÃÀå °³¿ä, ÁÖ¿ä ºê·£µåÀÇ »ç·Ê ¿¬±¸, ÃֽŠÆÇ¸Å·®, °ú°ÅÀÇ ¼ºÀå·ü, Àå±â ¿¹Ãø, ÆÇ¸ÅÀÇ ´Ü±â ¿¹Ãø µî¿¡ °üÇÑ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

°³¿ä

ºê¶óÁú

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

Áß±¹

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

ÇÁ¶û½º

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

µ¶ÀÏ

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

Àεµ

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

ÀÌÅ»¸®¾Æ

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

ÀϺ»

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

·¯½Ã¾Æ

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

¿µ±¹

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • Àü¸Á

¹Ì±¹

  • °³¿ä
  • Àü½Å¼º °¨±â¡¤ÀÎÇ÷翣ÀÚ
  • ÁøÇؾà
  • ÀÎÈÄÅë¾à¡¤¾à¿ë Á¦°ú
  • ±¹¼Ò¼º ÃæÇ÷Á¦°ÅÁ¦
  • Àü½Å¼º ÃæÇ÷Á¦°ÅÁ¦
  • ü½ºÆ® ·´(¹ã)¡¤ÈíÀÔÁ¦
  • ¾Ë·¹¸£±â Ä¡·áÁ¦
  • õ½ÄÀÇ Ä¡·á
  • Àü¸Á

ºê·£µå »ç·Ê ¿¬±¸

  • Claritin
  • Mucinex
  • Otrivin
  • Strepsils
  • Vicks
  • Zarbee's

Àü¸Á

KSA 20.11.19

KEY FEATURES OF THIS REPORT:

  • In-depth exploration of the CCA market
  • Case studies of key CCA brands
  • Latest mid-year 2020 sales from DB6
  • Historical growth rates back to 2015 from DB6
  • Longer-term forecasts to 2024 & 2029
  • Short-term sales forecasts to 2020 and 2021

Coverage of 10 major markets

  • Brazil
  • China
  • France
  • Germany
  • India
  • Italy Japan
  • Russia
  • UK
  • USA

With global sales of over $29bn, the CCA market grew by 4.2% in 2019, just ahead of the global consumer healthcare market (+3.9%). The largest categories Systemic cold & flu and Cough remedies are mature, fragmented and hampered by safety concerns. Allergy remedies expanded via Rx-to-OTC switches in recent years but their impact may have peaked. Topical decongestants and Chest rubs & inhalants enjoyed the strongest performances in 2019.

But what is next for the CCA market? It is projected to be the fastest-growing category in 2020 (according to DB6 estimates), boosted by coronavirus and reports of a high incidence of seasonal cold & flu at the start of 2020, but as consumers in most countries filled their medicine chests in Q1, this may dampen demand for the rest of the year. Have lockdown and physical distancing measures reduced the incidence of flu, colds, and non-Covid viruses? The rest of the year remains unpredictable with a rapid return to normal or a second wave of Covid-19 distinct possibilities.

  S&dragger;comprises Systemic decongestants (4%),Chest rubs & inhalants (3%),Asthma remedies (1%)

Key questions investigated in this report:

  • What are the key differences from market to market in terms of growth trends, regulations and competitive landscape?
  • Which marketers and brands stand out and what lessons can be learned?
  • How much has NPD benefited CCA and what is coming down the pipeline in the years ahead?
  • How have sales been affected by the Covid-19 pandemic?
  • What has been the impact of lockdown on cases of cold & flu and what are the implications for CHC medicines?
  • Which gaps in the market still exist and who is best placed to grab upcoming opportunities?

Table of Contents

Executive Summary

  • Global overview
  • Competitive landscape
  • Category review
  • NPD & innovation round-up
  • Beyond core CCA categories
  • Outlook

Brazil

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

China

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

France

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

Germany

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

India

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

Italy

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Allergy remedies
  • Outlook

Japan

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Allergy remedies
  • Outlook

Russia

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Outlook

UK

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Allergy remedies
  • Outlook

USA

  • Overview
  • Systemic cold & flu
  • Cough remedies
  • Sore throat remedies & medicated confectionery
  • Topical decongestants
  • Systemic decongestants
  • Chest rubs & inhalants
  • Allergy remedies
  • Asthma remedies
  • Outlook

Brand Case Studies

  • Claritin
  • Mucinex
  • Otrivin
  • Strepsils
  • Vicks
  • Zarbee's

Outlook & Prospects

Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q